McAlister FA, Zheng Y, Westerhout CM, et al. - Since it remains unclear if glycaemic control is related to cardiovascular outcomes in patients with type 2 diabetes (T2D), researchers examined the link between glycated haemoglobin (HbA_1c) and cardiovascular results in a placebo‐controlled randomized trial which showed no cardiovascular impact of sitagliptin in patients suffering from T2D and atherosclerotic vascular disease. They performed a secondary analysis with time to event analyses using multivariable Cox proportional hazard models, to analyze 14,656 TECOS participants. Each one‐unit increment in the time‐varying HbA_1c above 7% was found to be related to an adjusted hazard ratio of 1.21, 1.11, 1.18, and 1.10 for first heart failure (HF) hospitalization, all‐cause death, for death or HF hospitalization, and for non‐HF cardiovascular events, respectively. Findings revealed a U‐shaped association of glycated haemogobin with cardiovascular outcomes in patients suffering from T2D and atherosclerotic vascular disease, with nadir around 7%.